Healthpeak Properties insider trading
Every open-market purchase and sale by Healthpeak Properties's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Healthpeak Properties’s insiders pay?
From May 3, 2010 to May 13, 2026, 31 insiders reported 31 open-market purchases and 97 sales not made under a pre-set plan in Healthpeak Properties. Twelve months after each purchase was reported, the shares were −7.3% against the S&P 500 on average (median −4.7%), over 31 purchases with a full year of prices; 48% beat the index. After sales, the shares moved −11.6% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 11, 2011 into $24,733 by November 2, 2026, +6.1% a year. It held shares 48% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $40,542 (+9.7% a year), and held throughout $84,155 (+15.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Kirby Thomas D | Executive Vice President | 1 | +4.6% (1) | 100% | 17 | −3.9% (17) | September 8, 2016 |
| Anderson Scott A | EVP and CAO | 0 | — | — | 14 | −8.4% (14) | March 16, 2017 |
| Garvey Christine | Director | 0 | — | — | 12 | −24.2% (12) | February 23, 2023 |
| Klaritch Thomas | COO | 1 | −49.5% (1) | 0% | 7 | −21.3% (7) | March 9, 2023 |
| Young Kendall K | Senior Managing Director | 3 | +18.5% (3) | 67% | 4 | −17.6% (4) | February 15, 2018 |
| Bergschneider Jonathan M. | Executive Vice President | 0 | — | — | 6 | −15.4% (6) | August 24, 2016 |
| Brinker Scott M | President and CEO | 6 | −9.4% (6) | 50% | 0 | — | August 4, 2025 |
| Henning Edward J | Executive Vice President | 0 | — | — | 6 | −19.3% (6) | May 7, 2013 |
| Rhein Peter L | Director | 0 | — | — | 6 | +3.5% (6) | December 10, 2015 |
| Schoen Timothy M | EVP and CFO | 0 | — | — | 6 | −7.8% (6) | May 14, 2014 |
| Tate Susan M | Executive Vice President | 0 | — | — | 6 | −13.7% (6) | November 10, 2014 |
| Roath Kenneth B | Director | 0 | — | — | 5 | −8.0% (5) | February 21, 2013 |
| Lewis Sara Grootwassink | Director | 4 | −24.5% (4) | 25% | 0 | — | April 28, 2025 |
| Flaherty James F III | Chairman, Pres. and CEO | 0 | — | — | 2 | −14.1% (2) | February 27, 2013 |
| Gallagher Paul F | EVP and CIO | 0 | — | — | 2 | −19.5% (2) | March 4, 2013 |
| Hutchens James Justin | EVP & CHIEF INVEST OFC/SH+CARE | 2 | +2.2% (2) | 50% | 0 | — | February 11, 2016 |
| Kowalske Darren A | Executive Vice President | 1 | +5.3% (1) | 100% | 1 | −25.9% (1) | September 1, 2016 |
| Thomas John T | Director | 2 | −12.6% (2) | 50% | 0 | — | August 6, 2025 |
| Thompson Tommy G | Director | 2 | −10.5% (2) | 0% | 0 | — | May 28, 2025 |
| Bohn Scott R | CDO and Head of Lab | 0 | — | — | 1 | — | May 13, 2026 |
| Griffin R Kent Jr | Director | 1 | +35.7% (1) | 100% | 0 | — | May 15, 2018 |
| Herzog Thomas M | Eecutive Vice President | 0 | — | — | 1 | +12.1% (1) | May 9, 2011 |
| Hoffmann James P | Director | 1 | −4.7% (1) | 0% | 0 | — | November 12, 2015 |
| Lias-Booker Ava | Director | 1 | −32.7% (1) | 0% | 0 | — | April 29, 2025 |
| Lu Lihpang | Executive Vice President | 1 | +5.3% (1) | 100% | 0 | — | February 12, 2016 |
| Martin Lauralee | President and CEO | 1 | +9.0% (1) | 100% | 0 | — | February 11, 2016 |
| Mchenry Troy E. | EVP, Gen Counsel and Corp Sec | 1 | +4.6% (1) | 100% | 0 | — | February 16, 2016 |
| Mckee Michael D | Director | 0 | — | — | 1 | +13.9% (1) | June 1, 2011 |
| Sandstrom Katherine M | Director | 1 | −33.5% (1) | 0% | 0 | — | April 28, 2025 |
| Shelley-Kessler Pamela | Director | 1 | −33.5% (1) | 0% | 0 | — | April 28, 2025 |
| Stasinos John D. | Executive Vice President | 1 | +3.3% (1) | 100% | 0 | — | February 17, 2016 |
When several insiders traded Healthpeak Properties
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Healthpeak Properties in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −16.7% against the index. After 5 selling crowds, −5.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| April 30, 2025 | 6 buying | −17.7% | −22.7% | −32.7% |
| March 31, 2023 | 3 buying | −13.8% | −21.8% | −39.6% |
| September 30, 2016 | 4 selling | −16.9% | −17.7% | −37.9% |
| November 30, 2015 | 3 buying | −7.3% | −5.6% | −11.1% |
| May 30, 2014 | 5 selling | +0.3% | +0.5% | −13.2% |
| February 28, 2013 | 8 selling | −10.9% | −23.0% | −42.1% |
| May 31, 2011 | 7 selling | +7.8% | +10.1% | +12.7% |
| November 30, 2010 | 4 selling | +0.8% | +2.5% | +14.2% |